Faron Pharmaceuticals Oy (GB:FARN) has released an update.
Faron Pharmaceuticals Oy has announced a leadership change with Dr. Juho Jalkanen taking over as the new CEO starting May 2024, following Dr. Markku Jalkanen’s step down to continue as a board member. With a comprehensive background in the company and medical expertise, Dr. Juho Jalkanen is poised to lead Faron as they progress their key immunotherapy program, bexmarilimab, through clinical trials aimed at reprogramming immune cells to fight cancer.
For further insights into GB:FARN stock, check out TipRanks’ Stock Analysis page.
